196 related articles for article (PubMed ID: 27568329)
1. Pregnancy and acromegaly.
Muhammad A; Neggers SJ; van der Lely AJ
Pituitary; 2017 Feb; 20(1):179-184. PubMed ID: 27568329
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
3. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment in acromegaly.
Paisley AN; Trainer PJ
Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
[TBL] [Abstract][Full Text] [Related]
6. New perspectives in the medical treatment of acromegaly.
Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
[TBL] [Abstract][Full Text] [Related]
7. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
9. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy and acromegaly: a review.
Cheng V; Faiman C; Kennedy L; Khoury F; Hatipoglu B; Weil R; Hamrahian A
Pituitary; 2012 Mar; 15(1):59-63. PubMed ID: 21789529
[TBL] [Abstract][Full Text] [Related]
11. An update on clinical care for pregnant women with acromegaly.
Chanson P; Vialon M; Caron P
Expert Rev Endocrinol Metab; 2019 Mar; 14(2):85-96. PubMed ID: 30696300
[TBL] [Abstract][Full Text] [Related]
12. Acromegaly and pregnancy.
Caron P
Ann Endocrinol (Paris); 2011 Sep; 72(4):282-286. PubMed ID: 21820101
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
15. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
16. The medical treatment of acromegaly.
van der Lely AJ
Endokrynol Pol; 2007; 58(4):361-3. PubMed ID: 18058730
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
18. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
19. Medical therapy: options and uses.
Carmichael JD; Bonert VS
Rev Endocr Metab Disord; 2008 Mar; 9(1):71-81. PubMed ID: 18163211
[TBL] [Abstract][Full Text] [Related]
20. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy).
Colao A; Vandeva S; Pivonello R; Grasso LF; Nachev E; Auriemma RS; Kalinov K; Zacharieva S
Eur J Endocrinol; 2014 Aug; 171(2):263-73. PubMed ID: 24878680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]